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Introduction {#sec1}
============

Retinal diseases caused by the cell death of photoreceptors (PRs) and/or supporting retinal pigment epithelium (RPE), such as age-related macular degeneration and retinitis pigmentosa, are the increasingly significant cause of incurable sight loss. Cell replacement represents a potential vision restoration strategy for advanced stage of disease with severe cell loss ([@bib2], [@bib45]). While RPE replacement alone may be used for specific disease indications, transplantation of PRs---as a retinal sheet or as a suspension of dissociated cells---is required after extensive PR degeneration ([@bib11], [@bib35], [@bib45]). Prior studies in animal models revealed that transplantation of post-mitotic PR precursors, isolated from mouse neonatal retinae, might be feasible ([@bib27], [@bib32], [@bib36]). Donor PRs derived from mouse pluripotent stem cells (PSCs) have been transplanted into the subretinal space (SRS) of different blind mice models, showing integration into the degenerating retina, differentiation into mature PRs, and formation of synaptic connections, possibly leading to partial recovery of visual function ([@bib3], [@bib7], [@bib19], [@bib33], [@bib40]). However, recent work has indicated that functional recovery may be achieved by transferring of cytoplasmic material from transplanted mouse PRs to remaining host PRs, rather than through real integration into the recipient outer nuclear layer (ONL) ([@bib4], [@bib25], [@bib28], [@bib34], [@bib37]). It is unclear whether human PRs may also be able to transfer cytoplasmic material to host cells ([@bib47]).

The most promising source for the unlimited generation of human PRs for cell therapy is represented by human PSCs. Different protocols have been reported allowing for the differentiation of both rod and cone PRs starting from a serum-free floating culture of embryoid body-like aggregates (SFEB) ([@bib16], [@bib22], [@bib26]). Considerable progress has been made over the last few years with 3D retinal organoid formation from an optimized SFEB system ([@bib20], [@bib23], [@bib41], [@bib46]) or from adherent human PSCs ([@bib8], [@bib30]). Some of these protocols have been recently adapted to Good Manufacturing Practice (GMP) guidelines required for the generation of transplantable cells for future clinical applications ([@bib31], [@bib39], [@bib44]). Despite continuous improvements, efficiency in generating a homogeneous cell population of post-mitotic PR precursors, corresponding to the appropriate donor cell population for cell therapy, remains to be addressed. Ensuring safety is of particular importance; transplantable cells must be devoid of mitotically active cells or residual undifferentiated PSCs that could be teratogenic ([@bib40]). As genetic engineering or viral labeling of the cells are not suitable for clinical applications, several studies have been focusing on the identification of cell surface markers characterizing precursor and mature PRs derived from human induced pluripotent stem cells (hiPSCs) and in human retina ([@bib12], [@bib15], [@bib43]). However, low levels of both purity and cell yields resulting from the separation approaches used so far require further optimization, representing a challenge for future applications.

Using our GMP-compliant retinal differentiation protocol ([@bib31]), we have demonstrated that PRs express the cell surface antigen CD73, previously described for the enrichment of mouse PSC-derived PRs ([@bib14], [@bib33]). In this study, we reported a complete characterization of CD73+ cells during maturation of hiPSC-derived retinal organoids and we demonstrated that the simple CD73-based magnetic-associated cell sorting (MACS) results in selection of PRs. Transplantation of isolated CD73+ PRs in a rat model of retinal degeneration supported the usefulness of our separation strategy, which could be implemented for the development of stem cell-based therapy to treat retinal diseases due to PR cell death.

Results {#sec2}
=======

Expression of CD73 in hiPSC-Derived Retinal Organoids {#sec2.1}
-----------------------------------------------------

We first sought to determine the expression of the *NT5E* gene coding for the surface antigen CD73 during the maturation of hiPSC-derived retinal organoids, in floating culture conditions, based on our retinal differentiation protocol ([@bib31]). qRT-PCR analysis showed that *NT5E* (CD73) starts to be expressed at day 50 (D50); this expression sharply increases until 150 days of differentiation and is maintained in organoids at later stages of maturation. As expected, expression levels of PR-specific genes *CRX* and *RECOVERIN* (*RCVRN*) were also increased, with an earlier peak of induction around D100 ([Figure 1](#fig1){ref-type="fig"}A). CD73 was present in post-mitotic cells (Ki67--) committed in the PR lineage ([Figure S1](#mmc1){ref-type="supplementary-material"}). PR precursors in retinal organoids could further differentiate in all PR subtypes, rods, and red/green and blue cones, as shown by the increased expression of rhodopsin (*RHO*), red/green opsin (*OPN1LW/MW*), and blue opsin (*OPN1SW*), respectively ([Figure 1](#fig1){ref-type="fig"}B). Evaluation of CD73 expression by flow cytometry indicated that the percentage of CD73+ cells steadily increased from 7% ± 12% at D85 to 55% ± 2% at D200 of differentiation ([Figure 1](#fig1){ref-type="fig"}C, n = 10 organoids from N ≥ 3 differentiations, ^∗∗^p \< 0.01, Kruskal-Wallis test). Therefore, targeting the CD73+ cell population at different time of differentiation should result in isolating populations of either precursor or mature PRs ([Figure 1](#fig1){ref-type="fig"}D).Figure 1Analysis of CD73 Expression in hiPSC-Derived Retinal Organoids(A and B) qRT-PCR analysis of *NT5E* (coding for CD73) and PR markers during differentiation between D50 and D200 (mean ± SD; n = 5 organoids from N = 3 differentiations per time point). Gene expression at each time point is indicated relative to organoids at D50.(C) Percentage of CD73+ cells in organoids between D85 and D200 of differentiation analyzed by flow cytometry using CD73-FITC antibody (mean ± SD; n = 10 organoids from N ≥ 3 differentiations D85 versus D180 ^∗^p \< 0.05, D85 versus D200 ^∗∗^p \< 0.01, multiple comparisons Kruskal-Wallis test).(D) Schematic summarizing temporal expression of CD73 and mature PR markers in organoids.(E) Endogenous mCherry staining (red) and CRX immunolabeling (green) on solvent-cleared D75 organoid generated from the AAVS1:*CrxP*\_H2BmCherry hiPSC line.(F) Immunostaining showing the expression of CD73 in mCherry+ PRs in section of D100 AAVS1:*CrxP*\_H2BmCherry retinal organoid.(G) Dissociated mCherry+ cells (red) from D140 AAVS1:*CrxP*\_H2BmCherry retinal organoids co-expressing RECOVERIN (gray) and CD73 (green). Nuclei were counterstained with DAPI (blue) in the first left panel.Scale bars, 100 μm (E), 25 μm (F and G).

To evaluate if timing of CD73 expression was dependent on the hiPSC line used for the generation of the retinal organoids, we carried out additional characterization studies with another hiPSC line derived from adult Müller glial cells. Furthermore, to easily identify the entire PR population within the retinal organoids, we used this iPSC line to generate, using the CRISPR-Cas9 system, a fluorescent *CRX* hiPSC reporter line, in which a nuclear form of the fluorescent protein mCherry under the control of the mouse Crx promoter ([@bib6]) was inserted into the AAVS1 site ([Figure S2](#mmc1){ref-type="supplementary-material"}A). We selected a puromycin-resistant clone (CRX-c2), carrying a copy of the insert in both AAVS1 locus ([Figure S2](#mmc1){ref-type="supplementary-material"}B) for further retinal differentiation. qRT-PCR analysis of *NT5E* and PR-specific gene expression in retinal organoids from AAVS1:*CrxP*\_H2BmCherry hiPSC line ([Figures S2](#mmc1){ref-type="supplementary-material"}C and S2D) led to similar results obtained on organoids from hiPSC line 2 ([Figures 1](#fig1){ref-type="fig"}A and 1B). In whole retinal organoids, endogenous mCherry signal was visible by D49 and it allowed tracing the differentiating mCherry+ PRs ([Figure S2](#mmc1){ref-type="supplementary-material"}E). Immunostaining of sections from D100 organoids confirmed the expected nuclear localization of mCherry, due to the presence of the Histone-2B (H2B) sequence ([Figure S2](#mmc1){ref-type="supplementary-material"}F). By combining whole-mount immunostaining for CRX and a clearing procedure 3DISCO ([@bib1]) on D75 organoids, we showed that mCherry expression was restricted to CRX+ cells in the entire organoid ([Figures 1](#fig1){ref-type="fig"}E and [S2](#mmc1){ref-type="supplementary-material"}F; [Video S1](#mmc2){ref-type="supplementary-material"}), demonstrating the specificity of the mouse Crx promoter in the human context. The presence of both CONE ARRESTIN (hCAR)+/mCherry+ cells and RHODOPSIN+/mCherry+ cells identified by immunostaining ([Figure S2](#mmc1){ref-type="supplementary-material"}G) confirmed that mCherry+ cells were both cone and rods. Importantly, CD73 expression was restricted to mCherry+ cells both in retinal organoid sections ([Figure 1](#fig1){ref-type="fig"}F) and in dissociated cells from organoids, where all the RECOVERIN+ cells presented a mCherry+ nucleus ([Figure 1](#fig1){ref-type="fig"}G).

Video S1. Video of a D75 AAVS1::CrxP_H2BmCherry Retinal Organoid Labeled with Anti-CRX Green, Related to Figure 1

Enrichment of PRs by MACS Based on Expression of CD73 in Dissociated Retinal Organoid Cells {#sec2.2}
-------------------------------------------------------------------------------------------

Since we aimed at separating the PR population from organoids by targeting CD73, we developed a protocol based on the magnetic labeling of CD73+ cells, previously used to obtain PR enrichment from post-natal mice ([@bib5]). Efficiency of the MACS process was evaluated by flow cytometry using a PE-conjugated CD73 primary antibody on dissociated retinal organoids older than D100 of differentiation, because MACS at earlier stages did not lead to a satisfactory enrichment of CD73+ cells (data not shown). We showed that the MACS-positive fraction contained 87% ± 7% of CD73+ cells (n = 20 organoids, N = 3 differentiations; [Figure 2](#fig2){ref-type="fig"}A), a rate of enrichment consistent with previously published results from post-natal mouse retinae or retinal cells from mPSCs ([@bib5], [@bib33]). CD73+ fractions from D120 organoids revealed relative enrichment in CRX+/RECOVERIN+ cells (66% ± 15%) compared with the unsorted fractions (32% ± 7%) ([Figure 2](#fig2){ref-type="fig"}B), with the percentage of CRX+ cells being increased from 53% ± 10% in unsorted fractions to 79% ± 11% in CD73+ fractions (n = 10 images, N = 3 differentiations, ^∗∗∗∗^p \< 0.0001, two-way ANOVA with Tuckey\'s multiple comparisons test). MACS for CD73 was performed on D140 organoids generated from the AAVS1:*CrxP\_*H2BmCherry hiPSC line to validate the efficacy and the reproducibility of our separation strategy. As expected, almost all CD73+ cells in the MACS-positive fraction displayed mCherry+ nuclei (98% ± 0.7%, n = 12 images, N = 3 differentiations), as well as RECOVERIN-positive immunostaining ([Figure 2](#fig2){ref-type="fig"}C). A qualitative depletion of mCherry+ cells was observed in the CD73-- fraction, as opposed to the clear enrichment observed in the CD73+ fraction. Immunostaining for PAX6, corresponding to horizontal, amacrine, and retinal ganglion cells in retinal organoids ([@bib31]), demonstrated that PAX6+ cells constituted an abundant population in unsorted fractions from D120 organoids, while the MAC-sorted CD73+ cell population contained very few PAX6+ cells ([Figure 2](#fig2){ref-type="fig"}D). qRT-PCR analysis confirmed that *NT5E* expression level was significantly higher in CD73+ cells than in CD73-- cells at D120 ([Figure 2](#fig2){ref-type="fig"}E). Other markers of PR specification were expressed at increased levels in CD73+ cells ([Figure 2](#fig2){ref-type="fig"}E). The relatively modest increase of CRX+ cells could be due to the ontogenetic stage of organoids, where the differentiating CRX+/CD73-- cells present in D120 organoids were still present in the negative fractions. Ratios of gene expression levels between CD73+ and CD73-- fractions confirm increased expression in CD73+ cells for the PR genes analyzed ([Figure S3](#mmc1){ref-type="supplementary-material"}A). All together, these data support the use of CD73 as a marker of both differentiating cone and rod PRs and validate the MACS of CD73+ cells around D120 of differentiation as an efficient strategy to obtain a homogeneous and viable population of hiPSC-derived PR precursors.Figure 2Selection of hiPSC-Derived PRs by Targeting of CD73(A) Representative CD73-PE flow cytometry analysis plot (specific staining in blue, isotype control staining in red) on unsorted, and MAC-sorted CD73+ and CD73-- fractions from D120 organoids showing the percentage of CD73+ cells.(B) Immunofluorescence analysis of PR markers CRX and RECOVERIN in dissociated cells from D120 organoids (unsorted fraction) and in CD73+ and CD73-- fractions after MACS.(C) Immunolabeling of RECOVERIN+ cells in unsorted, and sorted CD73+ and CD73-- fractions from D140 AAVS1:*CrxP*\_H2BmCherry retinal organoids.(D) Exclusive expression of CRX and PAX6 in dissociated cells from D120 organoids (unsorted) and after MACS targeting CD73 (positive).(E) qRT-PCR expression analysis of PR-specific genes in cells from unsorted (gray), and CD73+ (red) and CD73-- (blue) fractions after MACS at D120 (mean ± SD; n = 25 organoids from N = 6 differentiations, ^∗^p \< 0.05, ^∗∗^p \< 0.01, multiple comparisons Kruskal-Wallis test). Gene expression is indicated relative to organoids at D120.(F) Quantitative analysis by flow cytometry of apoptotic (PI+) cells on unsorted and CD73+ fractions in dissociated cells from: unfrozen retinal organoids (unsorted and CD73+ fresh), freeze-thawed CD73+ cells, freeze-thawed retinal organoids (unsorted and CD73+ freeze-thawed organoids) (^∗^p \< 0.05, multiple comparisons Kruskal-Wallis test).(G) Co-expression of CRX and RECOVERIN in unsorted or sorted CD73+ cells from dissociated freeze-thawed organoids.Scale bars, 50 μm (B), 25 μm (C, D, and G).

With the perspective of developing a cell therapy product, we have tested the possibility to cryopreserve the isolated population of CD73+ cells directly after MACS. The evaluation of cell viability in freeze-thawed CD73+ cells by flow cytometry using propidium iodide (PI) revealed that 47% ± 7% of the cells are apoptotic (PI+) after thawing (compared with 4.6% ± 0.9% in fresh CD73+ cells, n = 15 organoids, N = 3 differentiations, ^∗^p \< 0.05, Kruskal-Wallis test) ([Figure 2](#fig2){ref-type="fig"}F). Having already developed a simple cryopreservation procedure of whole retinal organoids with no impact on CD73 expression ([@bib31]), we tested whether freeze-thawed organoids could still represent a source for MACS of viable CD73+ PR precursors. Retinal organoids, frozen at D90 of differentiation, were thawed and put back into floating cultures for an additional 2 weeks before performing MACS. In these conditions, MACS of CD73 cells still resulted in efficient enrichment of PR precursors, as shown by co-immunostaining with CRX and RECOVERIN ([Figure 2](#fig2){ref-type="fig"}G). The assessment of cell viability demonstrated that freeze-thawing resulted in a small, but not significant, increase in the number of apoptotic cells from 4.4% ± 1.9% to 15% ± 1% of PI+ cells in unsorted fractions from fresh and freeze-thawed organoids respectively (n = 15 organoids, N = 3 differentiations). MACS alone did not significantly affect cell viability in any condition: 4.4% ± 1.9% compared with 4.6% ± 0.9% and 15% ± 1% to 19.7% ± 4.2% of PI+ cells for fresh and freeze-thawed organoids respectively (n = 15 organoids, N = 3 differentiations) ([Figure 2](#fig2){ref-type="fig"}F).

Maturation of CD73+ PRs {#sec2.3}
-----------------------

To analyze more deeply the cell identity of CD73+ cells, MACS for CD73 was performed on 200-day-old retinal organoids containing mature rods and cones ([@bib30], [@bib31]). qRT-PCR analysis clearly showed a significant overexpression of both mature cone- (*OPN1SW* and *OPN1LW/M*) and rod-specific (*RHO*) genes in CD73+ cells compared with CD73-- cells ([Figures 3](#fig3){ref-type="fig"}A and [S3](#mmc1){ref-type="supplementary-material"}B), in agreement with previous immunostaining data revealing the co-expression of CD73 with CONE ARRESTIN, BLUE OPSIN, and RED/GREEN OPSIN in retinal organoids ([@bib31]). The increased expression of *NT5E*, as well as *CRX* and *RCVRN*, in the CD73-- positive fraction, confirmed the efficacy of the MACS process in retinal organoids from mature stages ([Figures 3](#fig3){ref-type="fig"}A and [S3](#mmc1){ref-type="supplementary-material"}B). qRT-PCR analysis of the different subunits of cyclic nucleotide-gated ion (CNG) channels, expressed in functional PRs, showed that the expression of both rod-specific CNG channel subunits (CNGA1 and CNGB1) and of cone-specific CNG channel subunits (CNGA3 and CNGB3) started between D50 and D100 and increased after D150 ([Figure 3](#fig3){ref-type="fig"}B). To assess whether the functionality of CD73+ cells was consistent with PR electrophysiological behavior, we studied CNG channel activity in dark-like conditions in adherent cultures of dissociated retinal organoids. By combining live two-photon calcium imaging with infra-red imaging, we monitored in CD73+ cells, labeled with a PE-conjugated CD73 antibody, the variations in intracellular Ca^2+^ levels in response to the addition of a cGMP analog (8-Br-cGMP), as described previously ([@bib20], [@bib31]). As dissociated cells from D120 organoids did not show any functional response (data not shown), experiments were performed in D190 dissociated cells when the expression of all subunits is optimal. Fura-2-loaded cells showed an increase in intracellular Ca^2+^ when exposed to 8-Br-cGMP, as demonstrated by decreased intracellular fluorescence (−22.42% ± 2.67%, n = 34, N = 8) ([Figures 3](#fig3){ref-type="fig"}C--3E). More importantly, the majority of the responsive cells were CD73-- PE+ cells ([Figure 3](#fig3){ref-type="fig"}F). Consistently with their gene expression profile, CD73+ cells displayed a PR-specific response to the cGMP analog, supporting the use of CD73 as a marker of the PR cell population.Figure 3Characterization of CD73+ Cells from Mature Retinal Organoids(A) qRT-PCR expression analysis of PR-specific genes in cells from unsorted (gray), and CD73+ (red) and CD73-- (blue) fractions after MACS at D200 (mean ± SD; n = 25 organoids from N = 6 differentiations, ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗^p \< 0.001, multiple comparisons Kruskal-Wallis test). Gene expression is indicated relative to organoids at D200.(B) qRT-PCR time course analysis of CNG channel subunits in organoids between D50 and D200 (mean ± SD; n = 5 organoids from N = 3 differentiation per time point). Gene expression at each time point is indicated relative to organoids at D50.(C) Representative examples of 2-Photon Fura2-AM fluorescence images (calcium imaging) obtained before (left) and during (right) application of 8-Br-cGMP on dissociated retinal cells at D190. White arrows 1 and 2 represent two responsive cells.(D) Infra-red (IR) image showing CD73-PE staining on dissociated retinal cells at D190. White arrows indicate responsive cells denoted 1 and 2 from image (C).(E) Fluorescence traces after application of cGMP analog on cells 1 and 2 displayed in (C and D), expressed as percentage change from baseline fluorescence (Δf/f%).(F) Percentage of CD73+ cells among the 8-Br-cGMP-responsive cell population (n = 19 from N = 5).Scale bars, 10 μm (C and D).

Safety Assessment of hiPSC-Derived Retinal Cells {#sec2.4}
------------------------------------------------

Since the use of PSC-derived cells is associated with the risk of the presence of potentially tumorigenic undifferentiated cells ([@bib40]), we evaluated by immunofluorescence the presence of residual undifferentiated PSCs and mitotic cells in retinal organoids. No expression of pluripotency markers OCT4, NANOG, or SSEA-4 were detected in dissociated retinal cells from D120 organoids, excluding the presence of undifferentiated PSCs. In contrast to undifferentiated hiPSC colonies ([Figure 4](#fig4){ref-type="fig"}A), very few cells were positive for the mitotic marker Ki67 at D120, corresponding to remaining retinal progenitor cells ([Figure 4](#fig4){ref-type="fig"}B). These data demonstrated the rarity of proliferative cells already before the selection of the PR by MACS. The safety of both unsorted and sorted CD73+ cells was assessed by transplanting 300,000 unsorted cells or MAC-sorted CD73+ cells from D120 organoids in the SRS of adult immunodeficient NUDE rats. As expected, no hyper-proliferation was observed after 8 weeks in animals engrafted with differentiated retinal cells ([Figure 4](#fig4){ref-type="fig"}C). Half of the NUDE rats transplanted with undifferentiated hiPSCs developed tumors in the eye ([Figure 4](#fig4){ref-type="fig"}D). Immunostaining with antibodies specifically directed against a cytoplasmic (STEM 121) or a human nuclear antigen (HNA) demonstrated the presence of human cells in the SRS 8 weeks after transplantation with both unsorted and sorted CD73+ cells ([Figures 4](#fig4){ref-type="fig"}E and 4F). The absence of Ki67+ cells in the SRS confirmed that both transplanted unsorted and CD73+ cells do not contain mitotically active cells ([Figure 4](#fig4){ref-type="fig"}F), confirming that retinal cells derived from D120 organoids are suitable for safe transplantation studies.Figure 4Safety Assessment of hiPSC-Derived Retinal Cells(A) Immunostaining showing the expression of pluripotency markers OCT4, NANOG, and SSEA-4 in iPSC colonies (hiPSCs) but not in dissociated cells (unsorted) from D120 retinal organoids.(B) Immunolabeling for Ki67 protein, associated with cell proliferation, in a representative iPSC colony and dissociated cells from D120 retinal organoids. Note loss of Ki67 expression in retinal cells.(C) Table recapitulating the tumorigenicity test after subretinal transplantation into NUDE rats of dissociated hiPSCs and D120 unsorted or MAC-sorted CD73+ cells. Observations were made 8 weeks after the transplantation.(D) Example of eyeballs of NUDE rats 8 weeks after subretinal transplantation of hiPSCs (black arrow) compared with non-transplanted eye. Bottom panel illustrates H&E staining of cross-section of the same hiPSC-transplanted eye.(E) Representative confocal images showing the presence of human S121+ cells in the SRS of NUDE rat 8 weeks after transplantation of D120 unsorted cells or MAC-sorted CD73+ cells. Nuclei were counterstained with DAPI (gray).(F) Absence of double Ki67+/HNA+ cells in unsorted and sorted CD73+ grafted cells 8 weeks after transplantation. Nuclei were counterstained with DAPI (gray). Scale bars, 1 cm (D) (top panel), 1 mm (D) (bottom panel), 50 μm (A and B), 20 μm (E and F). SRS, subretinal space; rPR, rat photoreceptors.

Transplantation of Unsorted and CD73+ Cells into the Dystrophic P23H Rat Retina {#sec2.5}
-------------------------------------------------------------------------------

Next, we sought to study the transplantation competence of CD73+ cells in a host environment recapitulating degenerative conditions. The P23H transgenic rat, which carries a P23H mutated *Rhodopsin* transgene, is a well-characterized model of rod-cone dystrophies, displaying progressive PR degeneration starting from 1 month after birth ([@bib24]). We transplanted unsorted retinal cells or sorted CD73+ cells from D120 organoids into 6-week-old hemizygous P23H rats, corresponding to an intermediate stage of PR degeneration ([@bib24]). One week after transplantation, unsorted cells survived in the SRS, identified by the expression of human-specific markers, STEM121, HNA, and human cytochrome *c* oxidase (MTCO2) ([Figure 5](#fig5){ref-type="fig"}A). hiPSC-derived retinal cells do not seem to migrate into the host ONL. Instead, S121+ cells were densely packed in the SRS, forming a new distinct layer of cells between host PRs and RPE even 4 weeks after transplantation ([Figures 5](#fig5){ref-type="fig"}B and 5C). Interestingly, the primary antibody against RECOVERIN, directed against an epitope of the human protein, led to a stronger signal against human cells than against host rat PRs and bipolar cells ([Figure 5](#fig5){ref-type="fig"}C). Although the RECOVERIN staining in the rat retina was still clearly detectable and highly specific ([Figure 5](#fig5){ref-type="fig"}D), this difference in the signal intensity can be used as an additional strategy to distinguish the xeno-transplant. Another parameter allowing for a straightforward identification of transplanted cells was the striking difference in the size and heterochromatin distribution of the nuclei in rat and human PRs. Consistent with previous observations ([@bib8]), human nuclei were bigger in size ([Figure 5](#fig5){ref-type="fig"}E) with multiple chromocenters ([@bib38]); conversely rat PRs had smaller nuclei and highly condensed heterochromatin at their center ([Figure 5](#fig5){ref-type="fig"}E). While a large part of human transplanted cells stained with anti-RECOVERIN antibody, double S121+/PAX6+ cells were also detected ([Figure 5](#fig5){ref-type="fig"}F), confirming the heterogeneous identity of unsorted cells.Figure 5Transplantation of hiPSC-Derived Retinal Cells into a Rat Model of Retinal Degeneration(A) Identification of donor human cells 1 week after transplantation by using three different human-specific antibodies (red): STEM 121 (left), MTCO2 (center), and HNA (right).(B) Confocal mosaic image of D120 unsorted cell-transplanted eye showing the distribution of human S121+ cells in the SRS 4 weeks after transplantation. Arrowheads delimitate the spread of the grafted cells; the site of injection is indicated with an arrow.(C) Most transplanted human retinal cells (S121+ cells) coexpress RECOVERIN. Note that RECOVERIN staining is lower in rat cells than in human cells.(D) Example of RECOVERIN immunostaining in a non-grafted retina from P23H rat at 10 weeks of age. RECOVERIN antibody specifically labels rat PRs and part of the bipolar cells within the INL.(E) Size of nuclei area of transplanted human cells and endogenous rat PRs 4 weeks after transplantation (mean ± SD, n = 30 nuclei measured, N = 3 grafted retinas; ^∗∗∗∗^p \< 0.0001, Mann-Whitney test).(F) Some transplanted human S121+ retinal cells express the transcription factor PAX6.Nuclei were counterstained with DAPI (gray). Scale bars, 20 μm (A, C, D, and F), 500 μm (B). SRS, subretinal space; ONL, outer nuclear layer, INL, inner nuclear layer; RGC, retinal ganglion cell layer.

In contrast to unsorted cells, xeno-grafts with CD73+ cells gave rise to a homogeneous population of cells, co-expressing S121 and RECOVERIN ([Figure 6](#fig6){ref-type="fig"}A) and completely devoid of PAX6+ cells 4 weeks after transplantation ([Figure 6](#fig6){ref-type="fig"}B). Further characterization of grafted CD73+ cells showed a high enrichment in cones, stained by human-specific CONE ARRESTIN (hCAR) antibody, while only few RHODOPSIN+ cells were detected ([Figure 6](#fig6){ref-type="fig"}C). hCAR+ cells corresponded predominantly to red/green cones ([Figure 6](#fig6){ref-type="fig"}D) and few human HNA+ cones expressed BLUE OPSIN ([Figure 6](#fig6){ref-type="fig"}E). When the host PRs are mostly degenerated in some animals, human PRs could be directly in contact with the host inner nuclear layer (INL), and the expression of the pre-synaptic protein RIBEYE could be observed as immunoreactive spots, distributed at the extremities of hCAR+ cells ([Figure 6](#fig6){ref-type="fig"}F). Immunostaining with PKCα antibody allowed the visualization of tight apposition between human S121+ cells and PKCα+ bipolar cells 4 weeks after transplantation ([Figures 6](#fig6){ref-type="fig"}G and 6G′).Figure 6Transplantation of hiPSC-Derived CD73+ Photoreceptors into the P23H Rat Model of Retinal Degeneration(A) Human S121+ cells co-expressing PR marker REVOVERIN located in close proximity to the rat INL. The residual rat PRs are delimited by the white dotted line.(B) Absence of double S121/PAX6-positive cells. Transplanted CD73+ cells labeled by S121 are in close proximity with host PAX6+ cells within the INL. Arrowheads indicate residual rat PR nuclei.(C) Labeling of human cone PRs by human-specific CONE ARRESTIN antibody (hCAR) and rod PRs by RHODOSPIN antibody. Arrowheads indicate human RHODOSPIN+ cells. Residual rat Rhodopsin+ PRs are delimited by the white dotted line.(D) Human S121+ cells co-expressing cone PR marker R/G OPSIN. Residual S121-- rat PRs (arrowheads) can be recognized by their nuclei features (smaller size and brightness).(E) Some human HNA+ cells express blue cone marker BLUE OPSIN (arrowheads).(F) Staining for synaptic protein RIBEYE and human CONE ARRESTIN (hCAR) showing localized punctate RIBEYE expression in human cone PRs directly in contact with the INL.(G) Rat PKCα+ bipolar cells are in close proximity to human S121+ cells inserted within the host ONL. The area delimited by the line indicates the location of high-magnification images presented in (G\').All observations were made 4 weeks after transplantation. Nuclei were counterstained with DAPI (gray). Scale bars, 20 μm (A--D), 10 μm (E--G′). SRS, subretinal space; rPR, rat photoreceptors; INL, inner nuclear layer; RGC, retinal ganglion cell layer.

In a few animals (n = 2/7) we observed, at 10 weeks post-transplantation, clusters of human PRs co-expressing S121 and RECOVERIN intercalated in the host retina ([Figure 7](#fig7){ref-type="fig"}A), indicating the ability of CD73+ cells to survive for a relatively long time in the presence of immunosuppressive treatment. The limited efficacy of the immunosuppressive regimen and possible blood-retina barrier damage subsequent to surgery could explain the limited number of animals in which human cells can be detected 10 weeks after transplantation. Human S121+ PRs were located in close proximity to the rat PKCα+ bipolar cells ([Figure 7](#fig7){ref-type="fig"}B). As in xeno-grafts analyzed 4 weeks after transplantation ([Figure 6](#fig6){ref-type="fig"}), again a large part of transplanted human HNA+ cells corresponded to cones (hCAR+ cells), even though few rods co-expressing bright RECOVERIN and RHODOPSIN can be observed ([Figures 7](#fig7){ref-type="fig"}C and 7D). Interestingly, some of the transplanted hCAR+ cones closest to the host INL expressed the pre-synaptic marker RIBEYE ([Figures 7](#fig7){ref-type="fig"}E and 7E′). Consistently, some of the rat PKCα+ bipolar cells closest to the human cells, distinguishable by their nuclear morphology, expressed RIBEYE at their synaptic terminals extending into the outer plexiform layer ([Figures 7](#fig7){ref-type="fig"}F and F′).Figure 7Long-Term Survival of Transplanted CD73+ Cells(A) CD73+ human PRs, co-expressing S121 and RECOVERIN, are intercalated within the rat retina.(B) Example of the distribution of human S121+ cells in close proximity to rat PKCα+ bipolar cells.(C) Transplanted PRs co-expressing human CONE ARRESTIN (hCAR) and human marker HNA. The residual rat PRs are delimited by the white dotted line.(D) Staining for human and rat rod PRs with RHODOPSIN and RECOVERIN antibodies.(E) RIBEYE protein expression in the rat outer plexiform layer close to human cone PRs (hCAR+ cells). The area delimited by the line indicates the location of the high-magnification image presented in (E\').(F) RIBEYE protein expression in close proximity to the synaptic terminals of rat PKCα+ bipolar cells. The area delimited by the line indicates the location of the high-magnification image presented in (F\').All observations were made 10 weeks after transplantation. Nuclei were counterstained with DAPI (gray). Scale bars, 50 μm (A and B), 20 μm (C--E and F), 5 μm (E′ and F′). SRS, subretinal space; rPR, rat photoreceptors; INL, inner nuclear layer; RGC, retinal ganglion cell layer.

Discussion {#sec3}
==========

In this study, we have developed a strategy based on the MACS of CD73+ cells to efficiently isolate PRs from hiPSC-derived retinal organoids and we demonstrated that CD73+ PR precursors could be safely transplanted into a host retina. One of the major challenges ahead for the development of a stem cell-based therapy to replace PRs is to obtain a consistent cell therapy product by complying with GMP guidelines, with no variations in terms of purity, yields, and quality of the manufactured cells. Using our retinal differentiation protocol combined with CD73-- cell sorting, we obtained a large number of cells corresponding to a homogeneous population of PR precursors, as shown by *in vitro* and *in vivo* characterization. Our differentiation protocol is based on a feeder-free iPSC culture system and uses exclusively chemically defined xeno-free compounds. GMP-compliant MACS enrichment is already used in clinical trials ([@bib21]), with no negative impact or long-term side effects due to the microbeads at the surface of MAC-sorted cells ([@bib9]). Thus, our entire protocol to manufacture a cell therapy product should be easily GMP transferable. Moreover, MACS could be performed using cryopreserved organoids, ensuring the possibility to store the organoids at the appropriate stage of differentiation for downstream applications.

Despite a reasonable variability, an adequate number of viable CD73+ cells for transplantation can be still isolated by MACS. Starting from 20 million dissociated retinal cells at D120 of differentiation, MACS yielded 5 ± 1.8 million CD73+ cells, corresponding to the 25% ± 9% of the total cell population, demonstrating that large-scale production of a homogeneous PR precursor cell population can be reached. We proposed that 120-day-old retinal organoids represent the most suitable source of transplantable PRs, since at this stage the CD73+ cell population is mostly composed of immature PRs expressing CRX and RECOVERIN, but not OPSIN and RHODOPSIN. The precise definition of the ontogenetic stage of donor cells is very important for transplantation success, as previously demonstrated in mice, where only early post-natal PR precursors are able to efficiently integrate into the retina ([@bib27], [@bib42]). The temporal profile of the expression of PR genes in our retinal organoids is very similar to the profile recently reported in human fetal retina ([@bib10], [@bib43]). Also, expression of genes in D115-D136 human fetal retina was correlated to mouse P2-P4 retina in a comparative analysis of human and mouse transcriptome during retinal development ([@bib10]), corroborating our choice of the differentiation stage of hiPSC-derived retinal organoids to isolate transplantable PR precursors. Recent transcriptome analysis of developing human PRs derived from PSCs should be also helpful for the isolation of PSC-derived PRs at the right stage of development, compatible for future transplantation studies ([@bib12], [@bib29], [@bib43]).

One major advantage of the separation strategy presented here relies on the targeting of one single-cell surface antigen, CD73. Positive selection of retinal cells expressing CD73 has been mainly focused on rods, using Nrl:GFP mice or AAVs carrying a rhodopsin-driven GFP to specifically label rods ([@bib5], [@bib13], [@bib14], [@bib33]). Nevertheless, CD73 has also been used for the enrichment of cone-like cells from a *Nrl−/−* mouse retina ([@bib32]). Very recently, a comparative analysis of the transcriptome of human fetal and iPSC-derived cones, identified with the use of an AAV2/9-pR2.1:GFP reporter, and screening for cell surface-specific markers for cones in GFP+ cells, has been reported. Interestingly, *NT5E* (CD73) expression was not upregulated in GFP+ cones isolated by fluorescence-activated cell sorting (FACS) ([@bib43]). This may be explained by the fact that CD73 is expressed by both rods and cones. Hence, in the absence of rods, no overexpression of CD73 is expected. Indeed, in our study, we found that hiPSC-derived retinal MAC-sorted CD73+ cells overexpress both rod- and cone-specific genes compared with CD73-- cells.

Remarkably, the enrichment in PR precursors obtained after CD73-based MACS from D120 retinal organoids is in agreement with recent data reported on human retinal tissues ([@bib15]). Indeed, FACS for CD73 from fetal retinae after 14 weeks of gestation allowed an enrichment for PRs, despite a large variability between different fetal samples (50% ± 24%). The ontogenetic stage of retinal organoids is critical for CD73-based PR selection, since previous RNA sequencing analysis in CRX-GFP+ cells isolated from hESC-derived retinal organoids younger than 90 days failed to identify CD73 as a marker of early PR precursors ([@bib12]).

Transplantation studies demonstrated that CD73-sorted PR precursors survive and mature into normal and degenerating rat retinae during several weeks. Surprisingly, a large part of transplanted CD73+ cells could be identified as cones in the SRS of P23H rats, suggesting that exogenous factors present within the host retina may favor either differentiation or survival of cones. Another explanation may reside in the temporal window of CD73 sorting, which may correspond to the peak of cone generation. Previous transplantation studies in mouse degenerative models had reported the presence of hiPSC-derived PRs within host mouse ONL, identified by GFP expression obtained via viral labeling ([@bib8], [@bib17], [@bib47]). Gonzalez-Cordero and colleagues were able to confirm the human origin of most of the virally labeled human PSC-derived PRs by immunostaining with human-specific nuclear antigen. Importantly, they also reported the presence of small numbers of GFP+/HNA-- within host ONL, whose morphology closely resembled that of mouse PRs, thereby demonstrating for the first time that human PSC-derived PRs can also engage in cytoplasmic material transfer following transplantation ([@bib8]). The absence of a morphological difference between human GFP+ cells and mouse PRs may lead to a reconsideration of the human identity of GFP+ cells in previous studies ([@bib17], [@bib47]). Donor-host cytoplasmic exchange has never been reported in transplantation studies in the rat retina. In our study, transplanted human PRs can be clearly distinguished from rat PRs thanks to both specific immunolabeling and cytological features. Remarkably, no HNA+ or S121+ cell displaying nuclear morphology peculiar to rat PRs was detected in host eyes, suggesting that transfer of cytoplasmic material between donor CD73+ PRs and host rat PRs does not seem to occur in the animal model presented here. Nevertheless, further studies would be necessary to undoubtedly exclude this process in the rat retina.

Despite the ability of CD73+ PRs to specifically respond to cGMP *in vitro,* no significant functional improvement was detected by electroretinography in P23H rats transplanted with unsorted or CD73+ cells compared with untreated eyes. Since human PRs were incorporated in a small area of the retina, more suitable strategies should be applied to determine the functionality of transplanted CD73+ cells. Also, in light of recent findings highlighting the structural divergence between rodent and human in proteins essential to PR synaptogenesis ([@bib18]), more closely related species such as non-human primates would be more appropriate to evaluate the efficacy of human PR grafts.

In summary, we have reported the generation and the separation of an hiPSC-derived PR precursor cell population amenable to GMP manufacturing and compatible for future cell replacement therapy. The simplicity and the robustness of our separation strategy represent a reliable source to obtain PRs, not only in the context of cell replacement, but also for a broad spectrum of applications, such as disease modeling or drug screening.

Experimental Procedures {#sec4}
=======================

See [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"} for detailed protocols and [Supplemental Information](#app2){ref-type="sec"} for antibodies ([Table S1](#mmc1){ref-type="supplementary-material"}) and qPCR probes ([Table S2](#mmc1){ref-type="supplementary-material"}).

MACS {#sec4.1}
----

Retinal organoids at various time points of differentiation were dissociated with papain (Worthington) according to the protocol described in [@bib31]. To remove residual aggregates, cell suspensions were filtered through a 30-μm strainer (Miltenyi Biotec). Dissociated cells were resuspended in MACS buffer and incubated first with CD73 antibody (BioLegend) for 10 min at 4°C at a dilution of 1:10 and then, after washing, with 20 μL of anti-mouse IgG1 MicroBeads (Miltenyi Biotec) per 10^7^ cells for 15 min at 4°C. Cells resuspended in 500 μL of MACS buffer were applied onto a pre-equilibrated mass spectrometry column fixed to a MACS separator (Miltenyi Biotec). The flow-through containing negative or unlabeled cells was collected by three washes with 500 μL MACS buffer. The positive fraction was eluted with 1 mL of MACS buffer following removal of the column from the magnet.

Cell Transplantation {#sec4.2}
--------------------

All protocols were approved by the local ethical committee (Charles Darwin ethical committee for animal experimentation C2EA-05) in strict accordance with French and European regulation for animal use in research (authorization number 05033). Cell suspension (4 μL) containing 300,000 cells in MACS buffer was injected with a trans-vitreal approach into the SRS of adult NUDE rats or 6-week-old hemizygous P23H rats. From 2 days before transplantation to the end of the follow-up, P23H rats were maintained under immunosuppression through cyclosporine treatment (210 mg/L) in the drinking water.
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